Please use this identifier to cite or link to this item:
|Title:||Pharmacogenetic effect of complement factor H gene polymorphism in response to the initial intravitreal injection of bevacizumab for wet age-related macular degeneration|
|Author:||Medina, Flavio Mac Cord|
Lopes da Motta, Augusto Alves
Takahashi, Walter Y.
Carricondo, Pedro Carlos
dos Santos Motta, Mario Martins
Melo, Monica B.
Vasconcellos, Jose Paulo C.
|Abstract:||To compare the functional and morphological response to the initial intravitreal (IV) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population. Twenty-five unrelated patients with treatment-naive exudative AMD underwent an IVT injection of 1.25 mg bevacizumab at the initial presentation (DO) and were reexamined 7 days (D7) and 28 days (D28) later. The time and extent of visual acuity (VA) and central retinal thickness (CRT) changes were evaluated according to the presence of the T1277C polymorphism. Results: In the homozygous risk group (CC), VA improvement was detected mostly from D7 to D28, while in the heterozygous (CT) and homozygous for the wild-type allele (TT) groups, functional response occurred earlier, from DO to D7. Morphological response to the first IVT injection of bevacizunnab was significant in the CT and TT groups, while the CC group presented no significant change in CRT up to D28. The CC variant of the CFH gene polymorphism T1277C is related to delayed functional and limited morphological response to the initial IVT injection of bevacizumab in exudative AMD patients in a sample of the Brazilian population|
|Appears in Collections:||FCM - Artigos e Outros Documentos|
CBMEG - Artigos e Outros Documentos
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.